Hepion Pharmaceuticals, Inc. SEC filings HEPA
Hepion Pharmaceuticals, Inc. has 723 filings in SEC EDGAR's recent list, going back to Aug 8, 2013. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 9, 2026 (material agreement, acquisition or sale of assets, unregistered share sale, officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| D | Filing | Aug 5, 2026 | — |
| D | Filing | Apr 22, 2026 | — |
| 25-NSE | Delisting notice | Jul 22, 2025 | — |
| NT 10-Q | Filing | May 15, 2025 | Mar 31, 2025 |
| UPLOAD | Letter from the SEC | Apr 24, 2025 | — |
| PRER14A | Filing | Apr 23, 2025 | — |
| NT 10-K | Filing | Apr 1, 2025 | Dec 31, 2024 |
| ARS/A | Filing | Feb 7, 2025 | Dec 31, 2023 |
| EFFECT | Filing | Jan 21, 2025 | — |
| CORRESP | Letter to the SEC | Jan 17, 2025 | — |
| CORRESP | Letter to the SEC | Jan 17, 2025 | — |
| CORRESP | Letter to the SEC | Jan 15, 2025 | — |
| CORRESP | Letter to the SEC | Jan 15, 2025 | — |
| CORRESP | Letter to the SEC | Jan 14, 2025 | — |
| CORRESP | Letter to the SEC | Jan 14, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 2, 2025 | — |
| 425 | Filing | Nov 21, 2024 | — |
| 425 | Filing | Sep 5, 2024 | — |
| 425 | Filing | Aug 7, 2024 | — |
| D | Filing | Jul 24, 2024 | — |
| 425 | Filing | Jul 22, 2024 | — |
| EFFECT | Filing | Jul 15, 2024 | — |
| CORRESP | Letter to the SEC | Jul 12, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 12, 2024 | — |
| NT 10-Q | Filing | May 15, 2024 | Mar 31, 2024 |
| NT 10-K | Filing | Apr 1, 2024 | Dec 31, 2023 |
| NT 10-Q | Filing | Nov 14, 2023 | Sep 30, 2023 |
| EFFECT | Filing | Nov 8, 2023 | — |
| CORRESP | Letter to the SEC | Nov 6, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 3, 2023 | — |
| D | Filing | Oct 3, 2023 | — |
| NT 10-K | Form nt 10-k | Apr 3, 2023 | Mar 31, 2023 |
| D | Filing | Nov 15, 2022 | — |
| NT 10-K | Filing | Mar 31, 2022 | Dec 31, 2021 |
| EFFECT | Filing | Nov 24, 2021 | — |
| CORRESP | Letter to the SEC | Nov 22, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 7, 2021 | — |
| EFFECT | Filing | Nov 24, 2020 | — |
| CORRESP | Letter to the SEC | Nov 20, 2020 | — |
| CORRESP | Letter to the SEC | Nov 20, 2020 | — |
| UPLOAD | Letter from the SEC | Nov 5, 2020 | — |
| EFFECT | Filing | Jun 17, 2019 | — |
| CORRESP | Letter to the SEC | Jun 14, 2019 | — |
| RW WD | Filing | Jun 13, 2019 | — |
| CORRESP | Letter to the SEC | Jun 13, 2019 | — |
| RW | Filing | Jun 13, 2019 | — |
| CORRESP | Letter to the SEC | Jun 12, 2019 | — |
| CORRESP | Letter to the SEC | Jun 5, 2019 | — |
| CORRESP | Letter to the SEC | Jun 5, 2019 | — |
| UPLOAD | Letter from the SEC | May 28, 2019 | — |
| EFFECT | Filing | Apr 24, 2019 | — |
| CORRESP | Letter to the SEC | Apr 22, 2019 | — |
| D | Filing | Mar 27, 2019 | — |
| EFFECT | Filing | Feb 19, 2019 | — |
| CORRESP | Letter to the SEC | Feb 13, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 11, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 11, 2019 | — |
| EFFECT | Filing | Jun 14, 2018 | — |
| CORRESP | Letter to the SEC | Jun 13, 2018 | — |
| CORRESP | Letter to the SEC | May 30, 2018 | — |
| UPLOAD | Letter from the SEC | May 29, 2018 | — |
| CT ORDER | Filing | Sep 15, 2016 | — |
| EFFECT | Filing | Mar 18, 2015 | — |
| CORRESP | Letter to the SEC | Mar 16, 2015 | — |
| CT ORDER | Filing | Mar 16, 2015 | — |
| UPLOAD | Letter from the SEC | Mar 12, 2015 | — |
| CERTNAS | Auto-generated paper document | Feb 25, 2015 | — |
| 8-A12B | Filing | Feb 24, 2015 | — |
| UPLOAD | Letter from the SEC | Oct 27, 2014 | — |
| PRER14A | Def 14a | Oct 27, 2014 | — |
| PRER14A | Preliminary revised proxy soliciting materials | Oct 23, 2014 | — |
| D | Filing | Oct 23, 2014 | — |
| UPLOAD | Letter from the SEC | Oct 23, 2014 | — |
| RW | Filing | Sep 26, 2014 | — |
| D | Filing | Aug 22, 2014 | — |
| D | Filing | Feb 14, 2014 | — |
| 10-12G/A | Filing | Feb 6, 2014 | — |
| UPLOAD | Letter from the SEC | Feb 3, 2014 | — |
| CT ORDER | Filing | Feb 3, 2014 | — |
| 10-12G/A | Filing | Dec 24, 2013 | — |
| UPLOAD | Letter from the SEC | Dec 11, 2013 | — |
| 10-12G/A | Filing | Nov 21, 2013 | — |
| UPLOAD | Letter from the SEC | Nov 4, 2013 | — |
| 10-12G/A | Filing | Oct 22, 2013 | — |
| UPLOAD | Letter from the SEC | Oct 10, 2013 | — |
| CORRESP | Letter to the SEC | Sep 20, 2013 | — |
| 10-12G/A | Filing | Sep 20, 2013 | — |
| UPLOAD | Letter from the SEC | Sep 5, 2013 | — |
| 10-12G | Registration of securities pursuant to section 12(g) | Aug 8, 2013 | — |
Showing 89 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HEPA (OTC), CTRVP (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Red Bank, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1583771
- Former names
- ContraVir Pharmaceuticals, Inc. (until Jul 23, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.